logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9115079 B1

PDFFull Text
Date of Patent:
Aug. 25, 2015

Filed:

Jul. 26, 2012

Ndm inhibitor

Applicants:

Akihiro Morinaka, Kawasaki, JP;

Kazunori Maebashi, Yokohama, JP;

Takashi Ida, Yokohama, JP;

Muneo Hikida, Himeji, JP;

Mototsugu Yamada, Kawasaki, JP;

Takao Abe, Yokohama, JP;

Inventors:

Akihiro Morinaka, Kawasaki, JP;

Kazunori Maebashi, Yokohama, JP;

Takashi Ida, Yokohama, JP;

Muneo Hikida, Himeji, JP;

Mototsugu Yamada, Kawasaki, JP;

Takao Abe, Yokohama, JP;

Assignee:

MEIJI SEIKA PHARMA CO., LTD., Tokyo-To, JP;

Attorney:

Wenderoth, Lind & Ponack, L.L.P.

Primary Examiner:

Taofiq A Solola

Int. Cl.
CPC ...
C07C 69/593 (2006.01); A61K 45/06 (2006.01); A61K 31/194 (2006.01); A61K 31/351 (2006.01); A61K 31/40 (2006.01); A61K 31/407 (2006.01); A61K 31/4164 (2006.01); C07D 309/06 (2006.01); C07C 279/08 (2006.01); C07C 217/18 (2006.01); C07C 233/65 (2006.01); C07C 235/20 (2006.01); C07C 237/22 (2006.01); A61K 31/216 (2006.01); A61K 31/225 (2006.01); A61K 31/4015 (2006.01); A61K 31/4174 (2006.01); A61K 31/4406 (2006.01); A61K 31/45 (2006.01); A61K 31/5375 (2006.01); C07C 69/608 (2006.01); C07C 69/612 (2006.01); C07C 69/618 (2006.01); C07C 69/732 (2006.01); C07D 207/12 (2006.01); C07D 211/46 (2006.01); C07D 213/55 (2006.01); C07D 233/64 (2006.01); C07D 295/108 (2006.01); C07C 63/66 (2006.01); C07C 57/13 (2006.01); C07C 57/26 (2006.01); C07C 57/30 (2006.01); C07C 57/42 (2006.01); C07C 57/48 (2006.01); C07C 57/50 (2006.01); C07C 59/46 (2006.01); C07C 59/64 (2006.01);
U.S. Cl.
CPC ...
C07C 69/593 (2013.01); A61K 31/194 (2013.01); A61K 31/216 (2013.01); A61K 31/225 (2013.01); A61K 31/351 (2013.01); A61K 31/40 (2013.01); A61K 31/407 (2013.01); A61K 31/4015 (2013.01); A61K 31/4164 (2013.01); A61K 31/4174 (2013.01); A61K 31/4406 (2013.01); A61K 31/45 (2013.01); A61K 31/5375 (2013.01); A61K 45/06 (2013.01); C07C 57/13 (2013.01); C07C 57/26 (2013.01); C07C 57/30 (2013.01); C07C 57/42 (2013.01); C07C 57/48 (2013.01); C07C 57/50 (2013.01); C07C 59/46 (2013.01); C07C 59/64 (2013.01); C07C 63/66 (2013.01); C07C 69/608 (2013.01); C07C 69/612 (2013.01); C07C 69/618 (2013.01); C07C 69/732 (2013.01); C07C 217/18 (2013.01); C07C 233/65 (2013.01); C07C 235/20 (2013.01); C07C 237/22 (2013.01); C07C 279/08 (2013.01); C07D 207/12 (2013.01); C07D 211/46 (2013.01); C07D 213/55 (2013.01); C07D 233/64 (2013.01); C07D 295/108 (2013.01); C07D 309/06 (2013.01);
Abstract

An objective of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of β-lactam antibiotics that have been inactivated as a result of decomposition by NDM. According to the present invention, there is provided an NDM inhibitor contains a compound represented by general formula (I):

Find Patent Forward Citations

Loading…